Senate of Canada: 11/1/12
Ottawa (November 1, 2012) – The absence of a standardized approach to research ethics review significantly impacts the time required to start up clinical trials in Canada and restricts the reporting of data in an open and transparent process. First and foremost, in changing the way we do clinical trials, must be the safety of Canadians and the effectiveness of the drugs they rely on, says a report from the Standing Senate Committee on Social Affairs, Science and Technology.
Titled Canada’s Clinical Trial Infrastructure: A Prescription for Improved Access to New Medicines, the report is the first phase in a study to examine and report on prescription pharmaceuticals in Canada. Over the course of 11 meetings, from 28 March to 30 May 2012, the committee heard testimony from Health Canada, Office of the Auditor General of Canada officials, representatives from the pharmaceutical and clinical trial industries, patient advocacy groups, medical, ethical and legal academics and representatives of research ethics boards. Read More